Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2024 07:00 ET | Source: Eisbach Bio GmbH

Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

Eisbach Bio received a $4.75M award from the Cancer Prevention and Research Institute of Texas for clinical development of its novel allosteric inhibitor.
September 16, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantFunds to Advance Development of Phase 3 Asset ...
July 23, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)...
June 03, 2024 12:57 ET | Source: 7 Hills Pharma

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
April 26, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
May 22, 2023 13:05 ET | Source: 7 Hills Pharma

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
April 11, 2022 10:00 ET | Source: Invectys, Inc.

Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS

Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...
June 25, 2021 11:30 ET | Source: Invectys, Inc.

INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021

Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
June 01, 2021 11:00 ET | Source: Invectys, Inc.

Invectys nominates Rosemary Williams, CPA, as Vice-President for Administration and Controller

Houston, TX, USA, June 01, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the...